CD123-Targeted Immunotherapeutics in: September 2016 R&D and Business Tracker for Bispecific Antibodies
CD123-Targeted Immunotherapeutics in:
September 2016 R&D and Business Tracker for Bispecific Antibodies
This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.
Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;
Scientific Publication Tracker
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
September 2016 R&D and Business Tracker for Bispecific Antibodies
This pdf report contains information about Bispecific Antibodies released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Bispecific Antibodies.
Featured presentations of September 2016 include the pipeline of CD123-targeted immunotherapeutics, the profile of Swiss pharmaceutical company Neovii Pharmaceuticals and the bispecific antibody profile of AMV-564 from Amphivena Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about Bispecific Antibodies covers;
- T-Cell redirecting bispecific cancer antibodies
- NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
- R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news
- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing
Scientific Publication Tracker
- Featured Bispecific Antibody Profile: AMV-564
- Featured Company Profile: Neovii Pharmaceuticals
- Featured Target or Technology Pipeline: CD123-Targeted Immunotherapeutics
- Antibody-Drug Conjugates
- Immunotoxins
- Fc-Engineered Antibodies
- T-cell Redirecting Bispecific Antibodies
- CAR T-Cells
Methodology:
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and La Merie Publishing’s proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.
Customized Update Service:
The above described information service represents our standard module. At an incremental cost, the service can be exclusively widened and customized to specific client needs, e.g. preparation of a preferred presentation format, inclusion of a watch list for tracking, executive summary etc.
